Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate CancerRichard Gagnon, Steven Yip, Tarek A. Bismar et al.|Clinical Genitourinary Cancer|2024Cited by 6
Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP)Michael McKenzie, Himu Lukka, Eric Winquist et al.|Journal of Clinical Oncology|2006Cited by 2
34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP)Michael McKenzie, Himu Lukka, K.N. Chi et al.|Radiotherapy and Oncology|2006Cited by 0